Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242007 | 0.87 | TP53 (0.35) | TP53ALDH1A1HPGDALOX15NPSR1 | |
| SCHEMBL23354918 | 0.87 | ALDH1A1 (0.49) | TP53JMJD6GABRA2GABRB2ALDH1A1 | |
| SCHEMBL16242073 | 0.86 | KDM4E (0.37) | TP53ALDH1A1ALOX15RAB9ANPC1 | |
| SCHEMBL16242077 | 0.86 | MYC (0.36) | TP53ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL23354916 | 0.84 | NOTUM (0.47) | TP53JMJD6GABRA2GABRB2ALDH1A1 | |
| SCHEMBL16242095 | 0.82 | PIK3CA (0.35) | TP53ALDH1A1ALOX15TSHRKDM4E | |
| SCHEMBL23354747 | 0.82 | ALDH1A1 (0.39) | TP53JMJD6GABRA2GABRB2ALDH1A1 | |
| SCHEMBL23354837 | 0.82 | TP53 (0.41) | TP53JMJD6GABRA2GABRB2ALDH1A1 | |
| SCHEMBL23354902 | 0.81 | NOTUM (0.47) | TP53GABRA2GABRB2ALDH1A1RAB9A | |
| SCHEMBL23354760 | 0.80 | GABRA2 (0.54) | TP53GABRA2GABRB2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725438-B2 | Substituted phenylazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725438-B2 | Substituted phenylazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725438-B2 | Substituted phenylazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| EP-3009433-B1 | 2-PHENYL-1,3-OXAZOLE AND 5-PHENYL-1,2,4-OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | DAIICHI SANKYO CO LTD (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-2805941-B1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-3009433-A1 | 2-PHENYL-1,3-OXAZOLE AND 5-PHENYL-1,2,4-OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | Daiichi Sankyo Company, Limited (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20160090375-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-31 | — | — | US | disclosed |
| US-20160090375-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-31 | — | — | US | disclosed |
| US-20160090375-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-31 | — | — | US | disclosed |
| US-20160081993-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160081993-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160081993-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-9233958-B2 | Substituted phenylazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | disclosed |
| US-9233958-B2 | Substituted phenylazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | disclosed |
| US-9233958-B2 | Substituted phenylazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20140357675-A1 | Substituted Phenylazole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| US-20140357675-A1 | Substituted Phenylazole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| US-20140357675-A1 | Substituted Phenylazole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2805941-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081993-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | IAPP, SLC5A1, GPR119 | TP53 1112/4885JMJD6 4438/4885GABRA2 1706/4885 |
| US-20160090375-A1 | SUBSTITUTED PHENYLAZOLE DERIVATIVE | IAPP, SLC5A1, GPR119 | TP53 1112/4885JMJD6 4438/4885GABRA2 1706/4885 |
| US-20140357675-A1 | Substituted Phenylazole Derivatives | IAPP, SLC5A1, GPR119 | TP53 1059/4885JMJD6 4415/4885GABRA2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.